New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

AbbVie Inc.

ABBV

Healthcare Drug Manufacturers General

AbbVie Inc.’s revenue for fiscal 2025 (year ended December 2025) was $61.2 billion, up 8.57% from fiscal 2024.

Revenue
+10.3%
EPS
+2,270.0%
Free cash flow
+9.97%
Total debt
+17.7%

Quarter to September 2026, against a year earlier

288.54 5.03 +1.77%
Market cap
$501.2B
P/E
48.8×
Fwd P/E FY26e
37.6×
Dividend yield
2.44%
F-score
8/9
ROIC
20.2%
Net debt / EBITDA
2.6×
Payout ratio
1.2×

Revenue to profit Fiscal 2025, year to Dec 31, 2025

Of every $100 of revenue, $6.92 was left as profit. Gross margin has risen two years running, from 62.4% to 70.2%. What is an income statement?

Revenue to profit, in billions of dollars and as a share of revenue
Revenue61.2100.0%
Cost of revenue−18.2−29.8%
Gross profit43.070.2%
Research & development−9.1−14.9%
Selling, general & admin−14.0−22.9%
Other operating costs−4.8−7.8%
Operating income15.124.6%
Other income, net−8.5−13.9%
Income tax−2.4−3.9%
Net income4.26.9%
RevenueOperating incomeNet incomeNet margin (right axis)
Revenue, operating income and net income, ten years
FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Revenue$25.6B$28.2B$32.8B$33.3B$45.8B$56.2B$58.1B$54.3B$56.3B$61.2B
Operating income$9.3B$9.5B$6.4B$13.0B$11.4B$17.9B$18.1B$12.8B$9.1B$15.1B
Net income$6.0B$5.3B$5.7B$7.9B$4.6B$11.5B$11.8B$4.9B$4.3B$4.2B
Net margin (right axis)23.2%18.8%17.4%23.7%10.1%20.6%20.4%9.0%7.6%6.9%
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Revenue
61,160.00 56,334.00 54,318.00 58,054.00 56,197.00 45,804.00 33,266.00 32,753.00 28,216.00 25,638.00
Revenue Growth
8.57% 3.71% (6.44%) 3.30% 22.69% 37.69% 1.57% 16.08% 10.06% 12.16%
Gross Profit
42,956.00 39,430.00 33,903.00 40,640.00 38,751.00 30,417.00 25,827.00 25,035.00 21,174.00 19,806.00
Operating Income
15,075.00 9,137.00 12,757.00 18,117.00 17,924.00 11,363.00 12,983.00 6,383.00 9,545.00 9,340.00
EBT
6,597.00 3,716.00 6,250.00 13,477.00 12,989.00 3,398.00 8,426.00 5,197.00 7,727.00 7,884.00
Income after Tax
4,233.00 4,286.00 4,873.00 11,845.00 11,549.00 4,622.00 7,882.00 5,687.00 5,309.00 5,953.00
Net Income Common
4,186.00 4,238.00 4,820.00 11,782.00 11,542.00 4,616.00 7,882.00 5,687.00 5,309.00 5,953.00
EPS (Diluted)
2.36 2.39 2.72 6.63 6.45 2.72 5.28 3.66 3.30 3.63
Shares (Diluted, Weighted)
1,773.00 1,773.00 1,773.00 1,778.00 1,777.00 1,673.00 1,484.00 1,546.00 1,603.00 1,631.00
Gross Margin
70.24% 69.99% 62.42% 70.00% 68.96% 66.41% 77.64% 76.44% 75.04% 77.25%
EBIT Margin
24.65% 16.22% 23.49% 31.21% 31.89% 24.81% 39.03% 19.49% 33.83% 36.43%
Net Profit Margin
6.84% 7.52% 8.87% 20.29% 20.54% 10.08% 23.69% 17.36% 18.82% 23.22%
Free Cash Flow Margin
29.13% 31.65% 40.62% 41.77% 39.13% 36.66% 38.39% 39.05% 33.42% 25.59%
EBITDA
24,061.00 21,999.00 25,684.00 26,584.00 26,445.00 17,834.00 15,000.00 8,148.00 11,046.00 10,529.00
EBIT
15,075.00 9,137.00 12,757.00 18,117.00 17,924.00 11,363.00 12,983.00 6,383.00 9,545.00 9,340.00

Show all line items

In millions of $ except per-share values · columns are period end dates · fundamentals updated Nov 18, 2026